Parabens in underarm products may lead to breast cancer in women

Parabens in breast tissue not limited to women who have used underarm products – New research into the potential link between parabens and breast cancer has found traces of the chemicals in breast tissue samples from all of the women in the study. Parabens are commonly used as preservatives in cosmetics, food products and pharmaceuticals.

Red wine drinking may reduce breast cancer risk in women

Moderate red wine drinking may help cut women’s breast cancer risk, Cedars-Sinai study shows – A glass of red wine with dinner may reduce breast cancer risk in women.

Drinking red wine in moderation may reduce one of the risk factors for breast cancer, providing a natural weapon to combat a major cause of death among U.S. women, new research from Cedars-Sinai Medical Center shows.

HER growth proteins do not predict outcome of herceptin treatment breast cancer patients

Proteins do not predict outcome of herceptin treatment in HER2-positive breast cancer – Precisely quantifying the amount of three different HER growth proteins, along with several other proteins believed linked to breast cancer, did not predict a patient’s outcome after treatment for HER2 Positive Breast Cancer with Herceptin, say Mayo Clinic researchers.

1 in 5 Americans has hearing loss, US

1 in 5 Americans has hearing loss — New nationally representative estimate shows wide scope of problem of loss of hearing – 20% of Americans over the age of 12 experience hearing loss in at least one ear. Nearly a fifth of all Americans 12 years or older have hearing loss so severe that it may make communication difficult, according to a new study led by Johns Hopkins researchers and published in the Nov. 14 Archives of Internal Medicine.

Alcohol increases breast cancer risk in women

New analysis from the Nurses’ Health Study: Association of alcohol with risk of breast cancer – Women who consume alcohol show an increase in their risk of developing breast cancer. This relation is stronger for women who drink in binges, are also taking post-menopausal hormonal therapy, and/or have low intakes of dietary folate.

Breast cancer risk increases with high hormone levels

Elevated hormone levels add up to increased breast cancer risk – Breast cancer risk may rise with high hormone levels – Eight different sex and growth hormones may rise the risk of breast cancer, each elevated hormone level increase risk by 16% in post-menopausal women.

Pfizer new drug could provide a new treatment option for postmenopausal women

Pfizer new drug BZA/CE could provide a new treatment option for symptomatic postmenopausal women with a uterus – Pfizer Inc. will announce new one-year results from the Selective estrogens, Menopause, And Response to Therapy [SMART]-5 Phase 3 study of the safety and efficacy of the investigational tissue selective estrogen complex (TSEC) bazedoxifene/conjugated estrogens (BZA/CE) at the 22nd annual meeting of the North American Menopause Society (NAMS), September_21-24 in Washington, D.C.

Soy isoflavone tablets not reducing bone loss or menopausal symptoms

Soy tablets not associated with reduction in bone loss or menopausal symptoms in women – Soy isoflavone tablets do not appear to reduce bone loss or menopausal symptoms in women within the first five years of menopause, revealed by researchers recently in a study reported in Archives of Internal Medicine.

Facial wrinkles may predict bone density in early menopause

Severity of facial wrinkles may predict bone density in early menopause – In postmenopausal women the appearance of the skin may offer a glimpse of the skeletal well-being, a relationship not previously described, said Lubna Pal, MD, a reproductive endocrinologist and associate professor at Yale School of Medicine, New Haven, Conn. The worse a woman’s skin wrinkles are during the first few years of menopause, the lower her bone density is.

Pfizer drug reduces breast cancer in high risk women

UB played major role in study on drug that reduces breast cancer in high-risk women — Buffalo enrolled more women than any other study site – The drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role, revealed at the American Society of Clinical Oncology annual meeting.